Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy Participants

Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy

Association Between Race/Ethnicity and Outcomes in Patients With Nonobstructive Hypertrophic Cardiomyopathy

Understanding the Impact of Placebo on Patient-reported Health Status: An Analysis From SEQUOIA-HCM

Effect of Aficamten Treatment for Up to 72 Weeks on Cardiac Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The SEQUOIA-HCM and FOREST-HCM CMR Sub-studies

Evaluation of Cytochrome P450 2C9, 2C19, and 2D6 Inhibition on the Pharmacokinetics of Aficamten in Healthy Participants

Concomitant Aficamten and Disopyramide in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical Trial

Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten

Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics